Allegations that a drug maker sought to keep low-cost generic alternatives off the market will be heard by the Supreme Court Monday. The appeal focuses on an industry practice dubbed “evergreening”: “It’s the fault of Parliament for creating this insane system”.
This content is for Blacklock’s Reporter members only. Please login to view this content. (Register here.)
